Skip to main content
Premium Trial:

Request an Annual Quote

John Mendlein

Editas Medicine has appointed John Mendlein to its board of directors. 

Mendlein is CEO of aTyr Pharma. He also serves on the boards of Fate Therapeutics (as vice chairman), Moderna Therapeutics, Pronutria Biosciences, and the emerging companies board of Biotechnology Industry Organization.

Prior to joining aTyr, he served as CEO of both Adnexus Therapeutics and Affinium Pharmaceuticals.

Mendlein holds a PhD in physiology and biophysics from the University of California, Los Angeles, a JD from the University of California, Hastings College of the Law and a BS in biology from the University of Miami.

The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.